Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm conversion therapy study of tislelizumab + GemCis + hepatic artery raltitrexed for locally unresectable intrahepatic cholangiocarcinoma
ChiCTR2400093975Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, gemcitabine, cisplatin and raltitrexed in intrahepatic cholangiocarcinoma (ICC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Started Dec 2024; status: recruiting.
02
Drugs
tislelizumabgemcitabinecisplatinraltitrexed
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2400093975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093975.